Stock Research: ScinoPharm

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

ScinoPharm

TSEC:1789 TW0001789006
28
  • Value
    76
  • Growth
    26
  • Safety
    Safety
    24
  • Combined
    29
  • Sentiment
    42
  • 360° View
    360° View
    28
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

ScinoPharm Taiwan Ltd. researches, develops, manufactures, and sells active pharmaceutical ingredients. The company operates in the pharmaceutical industry. It serves markets in the Americas, Europe, Australia, and Asia. In the last fiscal year, the company had a market cap of $445 million, profits of $40 million, and revenue of $104 million. The number of employees is not available.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 28 (better than 28% compared with alternatives), overall professional sentiment and financial characteristics for the stock ScinoPharm are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for ScinoPharm. The only rank that is above average is the consolidated Safety Rank at 76, which means that the company has a financing structure that is safer than those of 76% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 24, which means that the share price of ScinoPharm is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 26, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 42, which means that professional investors are more pessimistic about the stock than for 58% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
FTSE Taiwan
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
24 18 24 41
Growth
26 37 9 81
Safety
Safety
76 69 78 67
Sentiment
42 42 22 1
360° View
360° View
28 33 14 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
12 12 20 24
Opinions Change
50 50 1 50
Pro Holdings
n/a 40 20 41
Market Pulse
88 87 100 1
Sentiment
42 42 22 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
24 18 24 41
Growth
26 37 9 81
Safety Safety
76 69 78 67
Combined
29 30 20 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
15 12 7 36
Price vs. Earnings (P/E)
21 16 13 26
Price vs. Book (P/B)
52 35 41 65
Dividend Yield
50 36 49 53
Value
24 18 24 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
46 66 26 96
Profit Growth
60 20 10 84
Capital Growth
48 28 26 8
Stock Returns
22 48 51 61
Growth
26 37 9 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
73 67 71 68
Refinancing
58 49 65 67
Liquidity
67 55 63 41
Safety Safety
76 69 78 67

Similar Stocks

Discover high‑ranked alternatives to ScinoPharm and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Tsumura

TSE:4540
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Sumitomo Forestry

TSE:1911
Country: Japan
Industry: Homebuilding
Size: X-Large
Full Stock Analysis

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.